Baseline quality of life is associated with survival among people with advanced lung cancer

Lung cancer patients presenting with advanced cancer face low survival rates and a high symptom burden. There have been mixed findings for the association between survival and various patient reported outcomes (PROs). We used prospective data from 111 lung cancer patients with advanced stage III/IV...

Full description

Saved in:
Bibliographic Details
Published in:Journal of psychosocial oncology 2020-09, Vol.38 (5), p.635-641
Main Authors: Trejo, Mario J, Bell, Melanie L, Dhillon, Haryana M, Vardy, Janette L
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Cancer
Death & dying
Decision making
Female
Humans
Lung cancer
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Middle Aged
Neoplasm Staging
Pain
Patient Reported Outcome Measures
Patients
Prospective Studies
Quality of Life
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer patients presenting with advanced cancer face low survival rates and a high symptom burden. There have been mixed findings for the association between survival and various patient reported outcomes (PROs). We used prospective data from 111 lung cancer patients with advanced stage III/IV disease to investigate the association of survival with PROs (European Organization for Research and Treatment of Cancer Core-30 and Lung Module). Cox proportional hazard models were used to examine the individual association between several PRO measures and survival. Pain in chest and global quality of life (QoL) were found to have the strongest association with survival with a 20% increased hazard of death per 10% increase in pain in chest and 14% decrease in hazard of death per 10% increase in global QoL. Our results provide more evidence for the value of PRO data to inform clinical and patient decision-making.
ISSN:0734-7332
1540-7586
DOI:10.1080/07347332.2020.1765065